ImmunisBio, Poster Presentation at the Autumn Korean Society of Immunology Conference

Immunis Bio announced on the 13th that it will participate in the poster presentation and promotional booth at the '2023 KAI Korean Association of Immunologists' held at Songdo Convensia in Incheon until the 16th.

The presentation will cover the establishment of the ex-vivo culture process for a breast cancer-specific NK cell therapy tailored for breast cancer, and the high anticancer effect resulting from increased infiltration ability into breast cancer tissues.

A company representative stated, "Based on the research results, we plan to utilize them for the development of immune anticancer cell therapies with enhanced anticancer effects of NK cells and high culture efficiency."

At the Korean Association of Immunologists academic conference, keynote speeches were delivered by Nobel Prize nominee-level researchers from the United States and the Netherlands. More than 1,500 domestic and international immunology researchers, medical professionals, and businesspeople are expected to attend and discuss academic achievements that can elevate domestic immunology research to the next level.

CEO Kang Jeong-hwa said, "Over the four days at the Songdo Convensia promotional booth, we will exhibit ‘MYJ1633,’ an immune anticancer agent commercialized in Japan, Vietnam, and Malaysia, and use this as an opportunity to expand our network in line with the upcoming expansion of the domestic regenerative medicine market." She added, "We also plan to explain business diversification in the advanced bio sector through the introduction of the cell culture medium ‘IIB-CM,’ which is a functional cosmetic ingredient."

Founded in July 1974, the Korean Association of Immunologists (KAI) is a leading academic organization in the field of immunology in South Korea. It provides academic lectures for primary care physicians and complements and strengthens clinical immunology.

This content was produced with the assistance of AI translation services.